Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Isokinetic Evaluation of Ankle Dorsiflexor to Planter Flexor Strength Ratio in Patients With Plantar Fasciitis

perjantai 13. marraskuuta 2026 päivittänyt: Mostafa Mohamed El Saber Mohamed, Cairo University

The purpose of this study is to examine how people with plantar fasciitis differ from matched healthy controls in terms of ankle dorsiflexor/plantar flexor ratio (measured by Isokinetic dynamometry, IKD), pain intensity (measured by visual analogue scale, VAS), dynamic balance (assessed by Y-balance test), functional performance (assessed by foot function index, FFI), and ankle range of motion (measured by the goniometer).

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Interventio / Hoito

Yksityiskohtainen kuvaus

Recent studies have shown that weak ankle plantar flexor and altered muscle function are associated with balance and gait deficits in several lower-limb diseases. Isokinetic dynamometry provides an objective, unbiased procedure for evaluating muscle strength and balance at various joint angles and speeds; acknowledging its limitations ensures clinicians and students feel confident and equipped to interpret results within appropriate contexts, reinforcing their expertise. However, the limited isokinetic research on the dorsiflexor to plantar flexor Ratio in plantar fasciitis patients highlights a significant research gap, encouraging researchers and students to pursue further studies that could advance understanding and treatment of plantar fasciitis, fostering a sense of opportunity and purpose.

Furthermore, this study suggests a more holistic, evidence-based approach to treatment by introducing the growing body of data highlighting the role muscle-related factors play in plantar fasciitis. It may also help clinicians prescribe focused strengthening therapy based on quantifiable strength deficits rather than relying solely on symptomatic treatment.

Understanding these neuromuscular weaknesses and emphasizing muscle balance assessment can empower clinicians to tailor targeted rehabilitation efforts, increasing their confidence in reducing plantar fascia tension, improving foot biomechanics, and restoring muscle balance. Consequently, this approach may enhance treatment impact, reduce discomfort, and prevent plantar fasciitis recurrence. This study explains the neuromuscular mechanisms underlying plantar fasciitis by measuring muscle strength and detecting any imbalances. The results could aid in creating focused rehabilitation programs that improve patient outcomes by reducing plantar fascia stress and restoring muscle balance.

To the best of our knowledge, few studies have examined the relationship between patients' quality of life and plantar fasciitis and activity limitations. Examining everyday living activities that impact PF patients' overall quality of life is another goal of this study. Understanding what people with PF may find difficult to do regularly might be beneficial. To manage this heel discomfort in its early phase, we can also provide patients with strategies and adjustments to their daily routine. Their quality of life is enhanced as a result.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

102

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

      • Qina, Egypti
        • Cairo university
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 65 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

102 participants will be divided into two equal groups. 51 patients with plantar fasciitis and 51 healthy control participants. All of them will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain

Kuvaus

Inclusion Criteria:

  • Patients with plantar fasciitis (PF) will be diagnosed and classified by an orthopedic surgeon and a rehabilitation physician, ensuring exclusion of comorbidities such as systemic inflammatory conditions or neurological disorders that could confound assessments of muscle imbalance, thereby enhancing the validity of the findings.
  • Both females and males aged 18 to 65 years.
  • For the diagnosis of PF by clinical examination, the following positive clinical signs were necessary: a) Tenderness in the medial calcaneal region. B) Pain aggravated by prolonged standing or walking. C) Pain on first steps in the morning.
  • Positive windlass test (pain on big toe dorsiflexion).
  • Unilateral or bilateral PF with or without calcaneal spur.
  • Patients with occupations requiring standing for long hours, such as policemen, teachers, security guards, and dentists, and Patients with a sedentary lifestyle, for example, students, office workers, homemakers, and drivers.

Exclusion Criteria:

  • Non-steroidal anti inflammatory drugs use within the past week, along with recent physical therapy (less than six weeks) and steroid injections (less than six months), are exclusion criteria to prevent confounding factors that may influence pain assessment and diagnosis accuracy.
  • Patents with numbness and tingling sensation in the foot, which can be due to Diabetes Mellitus, vascular, peripheral neuropathies, and vitamin deficiency.
  • Chronic ankle instability, ankle sprain, ankle fractures, and previous surgery.
  • Calcaneal stress fractures, heel fat pad atrophy, and heel contusion.
  • Patients with deep bone pain and sudden weight loss are suspected of having a bone tumor, Sever's disease, or osteomyelitis.
  • Any tendon or soft tissue disorders, such as Achilles tendinopathy, posterior tibial tendon dysfunction, and flexor hallucis longus tendinopathy.
  • Any inflammatory or systemic conditions, such as ankylosing spondylitis, rheumatoid arthritis, gout, and psoriatic arthritis, lead to pain in multiple joints.
  • Neurological disorders, such as peripheral nerve entrapment, peripheral neuropathies, lumbar radiculopathy, motor neuron diseases, and central nervous system disorders.
  • Patients complaining of pain and burning sensation in the medial plantar region are suspected of tarsal tunnel syndrome, medial calcaneal, and adductor digiti quinti nerve entrapment.
  • Hepatic, renal, cardiovascular, and severe anemia.
  • Pregnant or breastfeeding women.
  • Severe psychosomatic or mental illness.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: OTHER
  • Aikanäkymät: CROSS_SECTIONAL

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Patients with plantar fasciitis

51 patients with plantar fasciitis will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain.

No intervention

Healthy control participants

51 healthy participants without plantar fasciitis will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain.

No intervention

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Ankle dorsiflexor peak torque at 30°/s
Aikaikkuna: At baseline (single assessment visit).

Ankle dorsiflexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle dorsiflexor peak torque at 120°/s
Aikaikkuna: At baseline (single assessment visit).

Ankle dorsiflexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle plantar-flexor peak torque at 30°/s
Aikaikkuna: At baseline (single assessment visit).

Ankle plantar-flexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle plantar-flexor peak torque at 120°/s
Aikaikkuna: At baseline (single assessment visit).

Ankle plantar-flexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle dorsiflexor-to-plantar-flexor peak torque ratio at 30°/s
Aikaikkuna: At baseline (single assessment visit).

The ratio of ankle dorsiflexor peak torque to plantar-flexor peak torque will be assessed during concentric isokinetic contractions using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque values will be recorded for both muscle groups, and the dorsiflexor-to-plantar-flexor ratio will be calculated and expressed as a percentage (%).

At baseline (single assessment visit).
Ankle dorsiflexor-to-plantar-flexor peak torque ratio at 120°/s
Aikaikkuna: At baseline (single assessment visit).

The ratio of ankle dorsiflexor peak torque to plantar-flexor peak torque will be assessed during concentric isokinetic contractions using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque values will be recorded for both muscle groups, and the dorsiflexor-to-plantar-flexor ratio will be calculated and expressed as a percentage (%).

At baseline (single assessment visit).

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Pain intensity
Aikaikkuna: At baseline (single assessment visit).

Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the maximum or worst pain. Participants will indicate their perceived pain intensity on the scale.

At baseline (single assessment visit).
Ankle dorsiflexion range of motion
Aikaikkuna: At baseline (single assessment visit).

Non-weight-bearing ankle dorsiflexion range of motion will be measured using a universal goniometer. Participants will be positioned prone with the knee flexed to 90°. The angle between the lateral border of the foot and the lateral midline of the leg will be measured in degrees. Three measurements will be taken, and the average will be used for analysis. Normal range of ankle dorsiflexion is approximately 0-20°.

At baseline (single assessment visit).
Ankle plantar-flexion range of motion
Aikaikkuna: At baseline (single assessment visit).

Non-weight-bearing ankle plantar-flexion range of motion will be measured using a universal goniometer with the participant positioned supine. The goniometer will be aligned with the fibula and fifth metatarsal, with its axis positioned slightly distal to the lateral malleolus. Three measurements will be taken, averaged, and expressed in degrees. Normal range of ankle plantar flexion is approximately 0-50°

At baseline (single assessment visit).
Dynamic balance - Anterior reach distance
Aikaikkuna: At baseline (single assessment visit).

Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the anterior direction. The maximum reach distance will be recorded.

At baseline (single assessment visit).
Dynamic balance - Posteromedial reach distance
Aikaikkuna: At baseline (single assessment visit).

Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the posteromedial direction. The maximum reach distance will be recorded.

At baseline (single assessment visit).
Dynamic balance - Posterolateral reach distance
Aikaikkuna: At baseline (single assessment visit).

Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the posterolateral direction. The maximum reach distance will be recorded.

At baseline (single assessment visit).
Foot function
Aikaikkuna: At baseline (single assessment visit).

Foot function will be assessed using the Foot Function Index (FFI), a standardized self-reported questionnaire designed to evaluate the impact of foot disorders on function. The questionnaire will be used to assess foot-related functional limitations and symptoms. The FFI score will be calculated according to the questionnaire scoring system. Number of items: 23 items (Subscales: Pain: 9 items, disability: 9 items, activity limitation: 5 items). Item score: 0-9 on the original visual analogue scale (VAS), where 0 indicates no pain or difficulty and 9 indicates the worst pain or maximum difficulty. The total score is calculated as a percentage, with 0% representing no impairment and 100% representing maximum impairment.

At baseline (single assessment visit).

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojen puheenjohtaja: Nabil A Abdellah, As.professor, Cairo University

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Perjantai 20. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 8. maaliskuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 15. maaliskuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 13. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 18. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 18. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • P.T.REC/012/006724

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa